Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

SHE: 000952

    • Home
    • SHE: 000952
Company Deals

Guangji Pharma to Raise $87 Million via Private Placement to Controlling Shareholder

Fineline Cube Feb 12, 2026

Hubei Guangji Pharmaceutical Co., Ltd. (SHE: 000952) announced plans for a private placement of up to...

Company Deals

Hubei Guangji Pharmaceutical Expands Ex-Hospital Market Presence with New Partnerships

Fineline Cube Nov 26, 2024

China-based Hubei Guangji Pharmaceutical Co., Ltd. (SHE: 000952) is poised to establish a strong presence...

Company Deals

Hubei Guangji Pharmaceutical Partners with Jiangnan University for Green Manufacturing Innovation Lab

Fineline Cube Jun 15, 2023

China-based Hubei Guangji Pharmaceutical Co., Ltd. (SHE: 000952) has announced a strategic partnership with Jiangnan...

Recent updates

  • Wenda Pharmaceutical Secures NMPA Breakthrough Therapy Designation for NHWD-870 in Rare NUT Carcinoma
  • European Commission Approves Bristol Myers Squibb’s Sotyktu for Psoriatic Arthritis Following FDA Clearance
  • CureGene Pharmaceutical Secures RMB 300 Million Series C to Advance Global Clinical Pipeline
  • Keymed Biosciences Secures NMPA Breakthrough Therapy Designation for CM336 in AL Amyloidosis
  • Innovent Biologics Secures Third Breakthrough Therapy Designation for IBI363 in MSS/pMMR Colorectal Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Wenda Pharmaceutical Secures NMPA Breakthrough Therapy Designation for NHWD-870 in Rare NUT Carcinoma

Company Drug

European Commission Approves Bristol Myers Squibb’s Sotyktu for Psoriatic Arthritis Following FDA Clearance

Company Deals

CureGene Pharmaceutical Secures RMB 300 Million Series C to Advance Global Clinical Pipeline

Company Drug

Keymed Biosciences Secures NMPA Breakthrough Therapy Designation for CM336 in AL Amyloidosis

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.